BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, Marfella R, Barbieri M. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1008922] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Dagogo-Jack S, Frederich R, Liu J, Cannon CP, Shi H, Cherney DZI, Cosentino F, Masiukiewicz U, Gantz I, Pratley RE. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. J Clin Endocrinol Metab 2023:dgac764. [PMID: 36702781 DOI: 10.1210/clinem/dgac764] [Reference Citation Analysis]
2 Sakai R, Sekimoto T, Koba S, Mori H, Matsukawa N, Arai T, Yokota Y, Sato S, Tanaka H, Masaki R, Oishi Y, Ogura K, Arai K, Nomura K, Sakai K, Tsujita H, Kondo S, Tsukamoto S, Suzuki H, Shinke T. Impact of Triglyceride-rich Lipoproteins on Early In-stent Neoatherosclerosis Formation in Patients undergoing Statin Treatment. Journal of Clinical Lipidology 2023. [DOI: 10.1016/j.jacl.2023.01.004] [Reference Citation Analysis]
3 Katano S, Yano T, Kouzu H, Nagaoka R, Numazawa R, Yamano K, Fujisawa Y, Ohori K, Nagano N, Fujito T, Nishikawa R, Ohwada W, Katayose M, Sato T, Kuno A, Furuhashi M. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors. Cardiovasc Diabetol 2022;21:285. [PMID: 36539818 DOI: 10.1186/s12933-022-01727-x] [Reference Citation Analysis]
4 Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina S, Cataldo V, Ghosh P, Franzese M, Puocci A, Paolisso P, Rafaniello C, Marfella R, Rizzo MR, Barbato E, Vanderheyden M, Barbieri M. Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 Inhibitors.. [DOI: 10.21203/rs.3.rs-2300456/v1] [Reference Citation Analysis]
5 Wang D, Liu J, Zhong L, Li S, Zhou L, Zhang Q, Li M, Xiao X. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045235] [Reference Citation Analysis]
6 Capuano A, Clementi E, Paolisso G. Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1040649] [Reference Citation Analysis]